OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Treatment Updates in Chronic Lymphocytic Leukemia

home / insights / cll-treatment-updates
Advertisement
TP53 and Deletion 17p as Prognostic Factors in CLL

EP. 1: TP53 and Deletion 17p as Prognostic Factors in CLL

March 31st 2018
Other Prognostic Factors in Chronic Lymphocytic Leukemia

EP. 2: Other Prognostic Factors in Chronic Lymphocytic Leukemia

March 31st 2018
Impact of Prognostic Factors on Clinical Decisions in CLL

EP. 3: Impact of Prognostic Factors on Clinical Decisions in CLL

March 31st 2018
Evolution of Biological Understandings in CLL

EP. 4: Evolution of Biological Understandings in CLL

March 31st 2018
Selecting the Optimal Frontline Therapy in CLL

EP. 5: Selecting the Optimal Frontline Therapy in CLL

March 31st 2018
Sequencing Strategies in Frontline CLL

EP. 6: Sequencing Strategies in Frontline CLL

March 31st 2018
Advertisement
Ibrutinib's Value as Frontline Therapy in CLL

EP. 7: Ibrutinib's Value as Frontline Therapy in CLL

March 31st 2018
Novel Frontline Combinations With Ibrutinib in CLL

EP. 8: Novel Frontline Combinations With Ibrutinib in CLL

March 31st 2018
Approaching Therapy for Relapsed/Refractory CLL

EP. 9: Approaching Therapy for Relapsed/Refractory CLL

March 31st 2018
CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

EP. 10: CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

March 31st 2018
Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

EP. 11: Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

March 31st 2018
Continuing Therapy in Relapsed/Refractory CLL

EP. 12: Continuing Therapy in Relapsed/Refractory CLL

March 31st 2018
Advertisement
Novel Approaches to Treating Relapsed/Refractory CLL

EP. 13: Novel Approaches to Treating Relapsed/Refractory CLL

March 31st 2018
Relapsed/Refractory CLL: Evaluating Other Novel Agents

EP. 14: Relapsed/Refractory CLL: Evaluating Other Novel Agents

March 31st 2018
The Evolving Treatment Landscape of CLL

EP. 15: The Evolving Treatment Landscape of CLL

March 31st 2018

Latest Conference Coverage

Dr Deek on the Investigation of Immune Cell Infiltration in MIBC

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

Dr Hoppe on the Rationale for the CheckMate 744 Trial in Hodgkin Lymphoma

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact